Death and the need for liver transplant were delayed in people with cirrhosis who received macrophage therapy.
Macrophage infusions reduced death risk and liver transplant need in cirrhosis patients in a clinical trial, marking a breakthrough in cell therapy for end-stage liver disease. For health-tech and biotech-adjacent managers, this validates bespoke immune cell therapies as a credible pipeline beyond oncology, with implications for procurement and partnership strategy in the medtech space.
29 May 2026
Death and the need for liver transplant were delayed in people with cirrhosis who received macrophage therapy.
Cirrhosis causes severe scarring of the liver ( (pictured, liver cells from a person with the disease). Credit: Microscape/Science Photo Library
Infusions of immune cells called macrophages have been linked to a reduction in the risk of death and the need for a liver transplant in people with cirrhosis1.
Access options
The University of Edinburgh scientists have developed a new cell therapy aiming to provide a potential alternative to liver…
Acute-on-chronic liver failure will be treated with device that cleans patients’ blood corrupted by toxins
Scientists at UC San Diego have unveiled a potentially game-changing treatment for MASH, a severe fatty liver disease affecting…
Machine learning model predicts whether donor is likely to die within the timeframe that liver remains viable
WASHINGTON (AP) – A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the…
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank…
